Naxifylline

• CAT Number: I008248
• CAS Number: 166374-49-8
• Molecular Formula: C18H24N4O3
• Molecular Weight: 344.42
• Purity: ≥95%
• Synonyms: BG9719; CVT-124; CVT124; CVT 124; Naxifylline;1,3-dipropyl-8-((1R,2R,4R,5R,6R)-3-oxatricyclo[3.2.1.02,4]octan-6-yl)-3,7-dihydro-1H-purine-2,6-dione
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 8-[(1S,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7H-purine-2,6-dione
• InChI: InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11+,13-,14+/m1/s1
• InChIKey: OQCJPFYWFGUHIN-GJKBLCTNSA-N
• SMILES: CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3C[C@H]4C[C@@H]3[C@H]5[C@@H]4O5

Naxifylline(CAT: I008248) is a potent adenosine A2B receptor antagonist with promising applications in respiratory and inflammation research. By selectively blocking the A2B receptor, it modulates adenosine-mediated signaling, which is implicated in airway inflammation, pulmonary fibrosis, and asthma. Naxifylline reduces pro-inflammatory cytokine release and attenuates fibrosis, making it a valuable tool for studying chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Its targeted mechanism also supports investigations into broader inflammatory pathways and the role of adenosine in tissue remodeling, offering insights for therapeutic development in respiratory and immune-mediated disorders.